Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973526 | 0.89 | PDPK1 (0.34) | ALDH1A1CYP2D6PDPK1MTORBCHE | |
| SCHEMBL7903447 | 0.88 | SSTR1 (0.39) | ALDH1A1PDPK1MTORBCHEALOX15 | |
| SCHEMBL8814600 | 0.87 | PDPK1 (0.40) | ALDH1A1CYP2D6MAPK1PDPK1MTOR | |
| SCHEMBL23867778 | 0.87 | ALDH1A1 (0.33) | ALDH1A1CYP2D6MAPK1PDPK1MTOR | |
| SCHEMBL26759988 | 0.87 | ALDH1A1 (0.33) | ALDH1A1CYP2D6MAPK1PDPK1MTOR | |
| SCHEMBL13129907 | 0.87 | PDPK1 (0.43) | ALDH1A1CYP2D6MAPK1PDPK1MTOR | |
| SCHEMBL9800986 | 0.85 | SLC6A2 (0.41) | ALDH1A1CYP2D6MAPK1LMNATSHR | |
| SCHEMBL6219718 | 0.83 | PDPK1 (0.44) | ALDH1A1PDPK1MTORLMNABCHE | |
| SCHEMBL13129987 | 0.83 | PDPK1 (0.47) | ALDH1A1CYP2D6MAPK1PDPK1MTOR | |
| SCHEMBL13129911 | 0.83 | PDPK1 (0.47) | ALDH1A1CYP2D6MAPK1PDPK1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087242-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2018-10-02 | — | — | US | disclosed |
| EP-2164521-B1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | PASTEUR INSTITUT (FR) | 2018-09-12 | — | — | EP | disclosed |
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | INSTITUT PASTEUR (FR) | 2015-02-19 | — | — | US | disclosed |
| US-8815239-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | INSTITUT PASTEUR (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087242-B2 | Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X | ST3GAL3, SI, STT3A | ALDH1A1 3090/4885CYP2D6 4359/4885MAPK1 1863/4885 |
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | ST3GAL3, SI, STT3A | ALDH1A1 3090/4885CYP2D6 4359/4885MAPK1 1863/4885 |
| US-20150050282-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X | ST3GAL3, SI, STT3A | ALDH1A1 3090/4885CYP2D6 4359/4885MAPK1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.